Current Clinical Trials
News & Events
Oxygen Biotherapeutics to Host 2013 Annual Meeting of Shareholders
MORRISVILLE, N.C.--(BUSINESS WIRE)--Dec. 3, 2013-- Oxygen Biotherapeutics, Inc., (NASDAQ: OXBT) a developer of oxygen-carrying therapeutics, today announced it will webcast its 2013 Annual Meeting of Shareholders on Wednesday, December 4, 2013 beginning at 9:00am ET at the offices of Smith, Anderson, Blount, Dorsett, Mitchell & Jernigan, L.L.P. located at Wells Fargo Capitol Center, 150 Fayettville Street, Suite 2300, Raleigh, NC 27601. Oxygen Biotherapeutics’ CEO John Kelley and CFO Michael Jebsen will be hosting the call.
A listen only teleconference will be available in real-time by dialing (877) 836-0197. To listen to the live webcast, please access the link https://event.webcasts.com/starthere.jsp?ei=1026689, at least 15 minutes prior to register. A replay of the call will be made available until June 4, 2014. more..
- To participate in our annual share holder meeting, call 877-836-0197 OR you can participate via webcast
Currently, we have one product candidate, Oxycyte PFC emulsion, in Phase IIb clinical trials in Switzerland and Israel for use in treating traumatic brain injury (TBI). This is a double-blind, placebo–controlled dose-escalation study. We have completed the first cohort and locked the database. The second cohort was initiated in May 2013.
Plans to expand our trials and to amend the protocol were completed in early 2013. At this time, we believe our study objectives as well as our safety and efficacy endpoints will remain the same under the new protocol. Furthermore, we believe these optimizations may enable us to conclude the study faster and more economically.
Phase I and IIa studies were conducted in the United States. A Phase IIb study protocol was filed with the FDA in the spring of 2008, but remains on clinical hold by the FDA due to questions raised by the regulatory agency. In 2011, we received a $2.07 million two-year cost reimbursement award from the U.S. Army to conduct safety related preclinical studies for Oxycyte PFC emulsion that will enable us to address the FDA's questions. The studies supported by this grant have examined the effect of Oxycyte on the immune system, platelet function and distribution, as well as the safety and efficacy of platelet transfusion, which can be conducted to evaluate the pharmacokinetics of PFCs in a relevant species. We believe the results of theses studies will support the safety profile of Oxycyte PFC emulsion.
For information on other clinical trials that are currently enrolling patients, please visit the following site: http://www.clinicaltrials.gov/